# Single Center Experience with Medical Cannabis in Gilles de la Tourette Syndrome > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medical-cannabis-gilles-de-la-tourette-syndrome-experience/ > **Published:** 2022-05-03T16:02:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:16:38-04:00 > **Clinical Summary:** Explore medical cannabis Gilles de la Tourette syndrome treatment outcomes and symptom relief from a single center study in Israel. --- Gilles de la Tourette syndrome (GTS) is a common neurodevelopmental disorder characterized by motor and phonic tics. This condition begins in childhood and continues throughout adulthood for half of its patients, with the current standard-of-care treatments offering only partial symptom relief while causing significant [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/). In Israel, [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) (MC) has been found by several small [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) to deliver symptoms relief for GTS with a relatively benign side effect profile. Subsequently, it was approved by the Israeli Ministry of Health for patients suffering from GTS suffering from significant impairments in daily living who failed to respond favorably to common medications. The assessment of its clinical benefit and adverse effects conducted by physicians at Tel-Aviv Medical Center recently revealed encouraging progress. Forty-two GTS patients treated with MC were interviewed via phone on treatment efficacy and adverse [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) of chronic MC consumption. On average, the global impression score of efficacy given by all patients was 3.85/5, indicating a quite high level of satisfaction. Thirty-eight (90%) reported benefits of some kinds from treatment. In particular, most patients considered reduction in tic severity, better sleep and improved mood as the major positive effects of MC. Only 10 patients (24%) elected to eventually stop treatment with MC for various reasons, which included severe side effects such as psychosis. Although these findings are encouraging, the author acknowledged that their study had a small number of participants and lacked rigorous controls, recommending that further clinical studies into this topic are highly needed. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid Clinical Trials for Anxiety and Tourette Syndrome](https://cedclinic.com/effects-cannabinoid-formulations-anxiety-clinical-trials/) Review [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) exploring cannabinoid treatments for anxiety and Tourette syndrome, highlighting emerging evidence and therapeutic potential. [Read More](https://cedclinic.com/effects-cannabinoid-formulations-anxiety-clinical-trials/) [Cannabis Reduces Tics in Tourette Syndrome: 306 Patients](https://cedclinic.com/cannabis-tourette-syndrome-tic-reduction-meta-analysis/) A meta-analysis of 306 patients shows [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) reduces tic severity in Tourette syndrome, supporting its therapeutic role. [Explore Study](https://cedclinic.com/cannabis-tourette-syndrome-tic-reduction-meta-analysis/) [Cannabinoid Formulations for Anxiety and Tourette Syndrome](https://cedclinic.com/cannabinoid-formulations-anxiety-treatment/) Discover different [cannabinoid formulations](https://cedclinic.com/brazil-cannabis-regulatory-framework-new-medical-rules/) studied for anxiety and Tourette syndrome symptom management and their clinical implications. [Learn More](https://cedclinic.com/cannabinoid-formulations-anxiety-treatment/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Single%20Center%20Experience%20with%20Medical%20Cannabis%20in%20Gilles%20de%20la%20Tourette%20Syndrome&url=https%3A%2F%2Fcedclinic.com%2Fmedical-cannabis-gilles-de-la-tourette-syndrome-experience%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fmedical-cannabis-gilles-de-la-tourette-syndrome-experience%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Single%20Center%20Experience%20with%20Medical%20Cannabis%20in%20Gilles%20de%20la%20Tourette%20Syndrome%20https%3A%2F%2Fcedclinic.com%2Fmedical-cannabis-gilles-de-la-tourette-syndrome-experience%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).